Komori
Share Issuance and Disposal4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Determination of the Offering Price and Other Terms

For the previously approved offering of common shares, the offering price and other terms have been finalized, including an offering price of ¥3,331 per share. In addition to the regular offering, an additional offering through an over-allotment will also be conducted.

Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
3842641600
Yen (total secondary offering price)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Offering of shares (offering through purchase underwriting by the underwriters) and offering through an over-allotment

発行・処分する株式数173,000Shares

not disclosed (regular offering); 173,000 shares (over-allotment)

Intended allottee
not disclosed (no specific allottee because this is an offering)
Offering price: ¥3,331 per share; underwriting price: ¥3,193.60 per share
Total issue value

Total offering price: ¥3,842,641,600; total over-allotment offering price: ¥576,263,000; total underwriting price: ¥3,684,136,960

Amount of funds to be raised
not disclosed (no funds raised by the company because this is a secondary offering)
発行済株式総数

not disclosed (this is an offering and does not involve the issuance of new shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Offering structure
Overallotment
173,000 shares offered; green shoe option exercise period: 13 April 2026 to 23 April 2026
Basis for determining the amount to be paid
A 3.03% discount to the closing price of ¥3,435 on 6 April 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalOffering of shares (offering through purchase underwriting by the underwriters) and offering through an over-allotment
Number of shares to be issued or disposed ofnot disclosed (regular offering); 173,000 shares (over-allotment)
Issue price and disposal priceOffering price: ¥3,331 per share; underwriting price: ¥3,193.60 per share
Total issue valueTotal offering price: ¥3,842,641,600; total over-allotment offering price: ¥576,263,000; total underwriting price: ¥3,684,136,960
Amount of funds to be raisednot disclosed (no funds raised by the company because this is a secondary offering)
Intended allotteenot disclosed (no specific allottee because this is an offering)
Dilution Ratenot disclosed (this is an offering and does not involve the issuance of new shares)
Basis for determining the amount to be paidA 3.03% discount to the closing price of ¥3,435 on 6 April 2026
Overallotment173,000 shares offered; green shoe option exercise period: 13 April 2026 to 23 April 2026
Items this document does not state (19)
Estimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyTotal number of issued sharesExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The offering price and other terms were determined for the offering of common shares approved on 30 March 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Determination of the Offering Price and Other Terms | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori